<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TROLEANDOMYCIN</span><br/>(troe-lee-an-doe-mye'sin)<br/><span class="topboxtradename">Tao<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">macrolide antibiotic</span><br/><b>Prototype: </b>Erythromycin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Derivative of oleandomycin, a macrolide antibiotic prepared from cultures of <i>Streptomyces antibioticus</i>. Chemically related to erythromycin and has similar range of antibacterial activity, but reportedly less effective; has high
         potential for toxicity.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against susceptible strains of pneumococci and group A beta-hemolytic streptococci. Cross-sensitivity with erythromycin
         reported.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute, severe infections of upper respiratory tract caused by susceptible strains of pneumococci and group A beta-hemolytic
         streptococci.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to any of the macrolide antibiotics; bacteriemia; patients receiving pimozide; use for prophylaxis
         or for minor infections; pregnancy (category C); porphyria.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired liver function; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Upper Respiratory Tract Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250500 mg q6h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 6.611 mg/kg (125250 mg) q6h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach (1 h before or 2 h after meals).</li>
<li>Give in evenly spaced intervals throughout the day, preferably around the clock, in order to maintain effective blood levels.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> GI:</span>
<span class="speceff-common">Abdominal cramps and discomfort, nausea,</span> vomiting, diarrhea, cholestatic jaundice. <span class="typehead">Body as a Whole:</span> Allergic reactions (urticaria, skin rash, <span class="speceff-life">anaphylaxis</span>); superinfections. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Troleandomycin may cause false elevations of <span class="alt">urinary 17-ketosteroids</span>
<span class="alt">(Drekter),</span> and <span class="alt">17-hydroxycorticosteroids</span>
<span class="alt">(Porter-Silver method).</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase levels of <b>carbamazepine,</b>
<span class="classification">cyclosporines</span>, and <b>theophylline</b> and their toxicity; <span class="classification">oral contraceptives</span> may cause cholestatic jaundice; <b>warfarin</b> may increase <b>prothrombin time (PT);</b>
<b>ergotamine</b> may induce ischemia and peripheral vasospasm. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Incompletely absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Distributed throughout body fluids; diffusion into CSF is poor unless meninges are inflamed. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in bile and urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Obtain periodic liver function tests in patients receiving drug longer than 10 d or in repeated courses.</li>
<li>Some patients develop an allergic type of hepatitis with right upper quadrant pain, fever, nausea, vomiting, jaundice, eosinophilia,
            and leukocytosis. Liver changes are reversible if drug is discontinued immediately.
         </li>
<li>Be aware that superinfections are most likely to occur in patients on prolonged or repeated therapy. Withdraw if symptoms
            present (see Appendix F), and start appropriate therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report signs of jaundice: Clay-colored stools, pruritus, yellow sclerae.</li>
<li>Do not stop drug before full course of therapy is completed. Do not interrupt and then restart therapy or increase or decrease
            dose or interval.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>